COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN PANAMA

被引：0
|
作者：
Ordonez, J. [1 ]
Valdes, R. [2 ]
Courville, K. [2 ]
Perez, R. [2 ]
Ordonez, A. [3 ]
Hidalgo Godinez, J. [4 ]
Villalobos, K. [4 ]
机构：
[1] True Consulting, Medellin, Colombia
[2] Caja Seguridad Social Panama, Panama City, Panama
[3] True Consulting, Medellin, Colombia
[4] AstraZeneca CAC, San Jose, Costa Rica
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA5
引用
收藏
页码：S504 / S505
页数：2
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN COSTA RICA
    Ordonez, J.
    Hernandez, F.
    Rodriguez, G.
    Estrada, J.
    Ordonez, A.
    Hidalgo Godinez, J.
    Villalobos, K.
    VALUE IN HEALTH, 2022, 25 (07) : S403 - S403
  • [2] COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN DOMINICAN REPUBLIC
    Ordonez, J.
    Dina, E.
    Alvarez, G.
    Rojas, L.
    Ordonez, A.
    Hidalgo Godinez, J.
    Villalobos, K.
    VALUE IN HEALTH, 2022, 25 (07) : S341 - S341
  • [3] COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE IN PANAMA
    Ordonez, J.
    Gonzales, L.
    Romero, A.
    Effio, J.
    Ordonez, A.
    Hidalgo Godinez, J.
    Villalobos, K.
    VALUE IN HEALTH, 2022, 25 (07) : S403 - S403
  • [4] Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
    Vareesangthip, Kriengsak
    Deerochanawong, Chaicharn
    Thongsuk, Dittaya
    Pojchaijongdee, Nuch
    Permsuwan, Unchalee
    ADVANCES IN THERAPY, 2022, 39 (03) : 1279 - 1292
  • [5] Cost-utility analysis of empagliflozin on chronic kidney disease progression in Thailand
    Dilokthornsakul, Piyameth
    Susantitaphong, Paweena
    Satirapoj, Bancha
    Singhan, Wanchana
    Ophascharoensuk, Vuddhidej
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 387 - 397
  • [6] Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
    Altawalbeh, Shoroq M.
    Alshogran, Osama Y.
    Smith, Kenneth J.
    VALUE IN HEALTH, 2018, 21 (12) : 1365 - 1372
  • [7] Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
    Kriengsak Vareesangthip
    Chaicharn Deerochanawong
    Dittaya Thongsuk
    Nuch Pojchaijongdee
    Unchalee Permsuwan
    Advances in Therapy, 2022, 39 : 1279 - 1292
  • [8] Cost-utility analysis in chronic kidney disease patients undergoing kidney transplant; what pays? A systematic review
    Senanayake, Sameera
    Graves, Nicholas
    Healy, Helen
    Baboolal, Keshwar
    Kularatna, Sanjeewa
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
  • [9] Cost-utility analysis in chronic kidney disease patients undergoing kidney transplant; what pays? A systematic review
    Sameera Senanayake
    Nicholas Graves
    Helen Healy
    Keshwar Baboolal
    Sanjeewa Kularatna
    Cost Effectiveness and Resource Allocation, 18
  • [10] COST-UTILITY ANALYSIS OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE IN COSTA RICA
    Ordonez, J.
    Quesada Chaves, D. F.
    Rodriguez, M.
    Poveda, J.
    Speranza, M.
    Ordonez, A.
    Hidalgo Godinez, J.
    Villalobos, K.
    VALUE IN HEALTH, 2022, 25 (07) : S360 - S360
12345